Irish drugmaker Shire will pay about $32 billion in cash and stock to buy Baxalta and strengthen its position in rare disease treatments. Treatments for rare diseases have become a hot and lucrative area of drug industry research in the past several years, with drugmakers testing hundreds in clinical trials .
Are you up for a challenge?
